The Latin America, Middle East and Africa Autoinjectors Market would witness market growth of 18.7% CAGR during the forecast period (2020-2026).
Epinephrine is considered the first line of treatment for allergic reactions or anaphylaxis. Pharmaceutical companies are bringing technologically advanced epinephrine autoinjectors (EAIs) treatment of anaphylaxis. With the advancement in technology including portable devices, innovative designs, autoinjectors with two auto-injectable doses in one device, autoinjectors made with a 0.5- or 0.75-mg dose of epinephrine for larger adults, the autoinjectors are experiencing higher rate of adoptability.
Also, autoinjectors made with a 0.1-mg dose of epinephrine for infants, autoinjectors with enhanced temperature stability and extended shelf life for epinephrine, weather-resistant casing, and devices that can update patients that the dosage was successfully delivered makes the device more user friendly. Factors that are being focused on for improvement of autoinjectors are removal force of safety cap, override force, ejection time, ejection dosage, needle activation force, needle length, dose setting & audible click detection. These technological advancements are anticipated to drive the adoption of autoinjectors significantly in the coming years.
The existing COVID-19 pandemic has brought about the implementation of a new set of protocols that target to decrease patient visits to hospitals and clinics if it is not emergency conditions in order to prevent the spread of the virus. In such a situation, the inclination for home-use autoinjectors has increased among patients who are suffering from allergies and chronic illnesses. This also safeguards susceptible high-risk populations from exposure to the virus while visiting to hospital.
Autoinjectors are being advanced to support improved concentrations and viscosity of drugs to lessen administration frequency, therefore growing adherence to acclaimed drug protocols. These factors facilitate an opportunity for the growth of the market of autoinjectors in the present COVID-19 scenario.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: Autoinjectors Market in LAMEA is expected to register a CAGR of 18.7% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
By Type
By Application
By End Use
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 